

Lenvatinib (LENVIMA)

Criteria for Use

January 2026

VA Pharmacy Benefits Management Services and National Formulary Committee

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

See the VA National Formulary Committee Monograph on this drug at the [PBM INTRAnet](#) site for further information.

Exclusion Criteria If the answer to ANY item below is met, then the patient should NOT receive lenvatinib.

- Major surgery within the prior 2 weeks
- Current serious wound that is not healing
- Any grade GI perforation or grade 3-4 fistula
- Arterial thromboembolic event within the previous 6 months
- QTc >480 ms¹
- Uncontrolled hypertension
- Untreated CNS metastases
- Pregnancy
- Lactating

¹ Monitor ECGs in patients with congenital long QT syndrome, congestive heart failure, bradyarrhythmias, or those who are taking drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics

Inclusion Criteria One of the following criteria must be met.

- Child-Pugh A, Barcelona Clinic Liver Cancer Stage C or B, unresectable hepatocellular carcinoma as first-line treatment
- Endometrial Carcinoma [mismatch repair proficient (pMMR)/microsatellite stable (MSI-S)] in combination with pembrolizumab, following prior systemic therapy and not a candidate for curative surgery or radiation
- Renal Cell Carcinoma, in combination with pembrolizumab, as first-line treatment
- Renal Cell Carcinoma, in combination with everolimus, following prior anti-angiogenic therapy
- Differentiated Thyroid Cancer, locally recurrent or metastatic radioactive iodine-refractory

Additional Inclusion Criteria All of the following criteria must be met.

- Care provided by a VA or VA Community Care oncology provider
- Goals of care and role of Palliative Care consult have been discussed and documented
- Eastern Cooperative Oncology Group Performance Status of 0 or 1

Additional Inclusion Criteria

- For females who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy and for 30 days after stopping treatment.

Other Justification

- _____